Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Florida Medicaid plan

Executive Summary

Pfizer has been approached by a "number of other states, and in fact, countries" to strike a Medicaid program deal similar to that in Florida, CEO Hank McKinnell tells analysts July 17. "We've had to make it very clear that this is a pilot and before we're really ready to replicate it we need to demonstrate that this program really works." Pfizer is offering Florida free drugs in exchange for continued unrestricted access to the state's Medicaid formulary (1"The Pink Sheet" May 21, p. 4). "I think for our industry, this is absolutely the right way to be going. But on the other hand, we haven't demonstrated that we can actually do this yet"

You may also be interested in...



Pfizer “Evolves” From Rx To Health Care Company: Fla. Medicaid Is Blueprint

Pfizer plans to follow the blueprint set by its disease management agreement in Florida to forge "creative" agreements with other public and private payors, CFO David Shedlarz told the J.P. Morgan health care conference in San Francisco Jan. 14

Pfizer “Evolves” From Rx To Health Care Company: Fla. Medicaid Is Blueprint

Pfizer plans to follow the blueprint set by its disease management agreement in Florida to forge "creative" agreements with other public and private payors, CFO David Shedlarz told the J.P. Morgan health care conference in San Francisco Jan. 14

Florida Medicaid Formulary Exclusions Are Not Final, Bristol Tells Investors

The exclusion of Pravachol and Plavix from Florida's initial Medicaid formulary should not be considered final, Bristol-Myers Squibb Worldwide Group Medicines President Richard Lane told an investor conference call July 25.

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel